$GNPX
Genprex Inc

2024 Q1 Form 10-K Financial Statement

#000143774924010426 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.720M $2.270M $13.44M
YoY Change -31.32% -35.07% 9.34%
% of Gross Profit
Research & Development $3.274M $3.713M $17.62M
YoY Change -38.34% 11.87% 53.05%
% of Gross Profit
Depreciation & Amortization $2.670K $5.000K $15.00K
YoY Change -33.52% -17.76% -41.35%
% of Gross Profit
Operating Expenses $3.274M $5.987M $31.08M
YoY Change -38.34% -12.24% 169.99%
Operating Profit -$5.997M -$31.08M
YoY Change -35.32% 30.4%
Interest Expense $27.85K $57.49K $215.1K
YoY Change -60.21% 3.4% 138.75%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.969M -$5.929M -$30.86M
YoY Change -35.12% -12.37% 29.99%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.969M -$5.929M -$30.86M
YoY Change -35.14% -12.37% 29.99%
Net Earnings / Revenue
Basic Earnings Per Share -$3.69 -$22.56
Diluted Earnings Per Share -$3.69 -$3.99 -$22.56
COMMON SHARES
Basic Shares Outstanding 1.910M 59.43M 1.368M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.217M $6.738M $6.738M
YoY Change -54.56% -67.85% -67.85%
Cash & Equivalents $8.217M $6.738M
Short-Term Investments
Other Short-Term Assets $1.011M $794.1K $794.1K
YoY Change -45.64% 64.0% 64.0%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $9.228M $7.532M $7.532M
YoY Change -53.73% -64.92% -64.92%
LONG-TERM ASSETS
Property, Plant & Equipment $4.023K $7.860K $7.860K
YoY Change -78.84% -65.87% -65.87%
Goodwill
YoY Change
Intangibles $790.5K $773.5K
YoY Change 9.52% 10.17%
Long-Term Investments
YoY Change
Other Assets $3.333M $10.00K $10.00K
YoY Change -0.78% -99.72% -54.17%
Total Long-Term Assets $3.337M $3.139M $3.139M
YoY Change -1.22% -13.1% -13.1%
TOTAL ASSETS
Total Short-Term Assets $9.228M $7.532M $7.532M
Total Long-Term Assets $3.337M $3.139M $3.139M
Total Assets $12.56M $10.67M $10.67M
YoY Change -46.12% -57.46% -57.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.152M $1.398M $1.398M
YoY Change -2.71% 215.54% 215.54%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.808M $3.254M $3.254M
YoY Change -21.25% 15.8% 15.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.808M $3.254M $3.254M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.808M $3.254M $3.254M
YoY Change -21.25% 15.8% 15.8%
SHAREHOLDERS EQUITY
Retained Earnings -$139.7M -$133.7M
YoY Change 24.66% 30.01%
Common Stock $1.923K $1.486K
YoY Change -96.3% -96.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.757M $7.416M $7.416M
YoY Change
Total Liabilities & Shareholders Equity $12.56M $10.67M $10.67M
YoY Change -46.12% -57.46% -57.46%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$5.969M -$5.929M -$30.86M
YoY Change -35.14% -12.37% 29.99%
Depreciation, Depletion And Amortization $2.670K $5.000K $15.00K
YoY Change -33.52% -17.76% -41.35%
Cash From Operating Activities -$5.298M -$4.969M -$24.74M
YoY Change -23.58% 8.33% 39.15%
INVESTING ACTIVITIES
Capital Expenditures $16.99K $11.38K $71.38K
YoY Change -13.45% -43.1%
Acquisitions
YoY Change
Other Investing Activities $1.170K $170.00 $170.00
YoY Change -99.57% -99.89%
Cash From Investing Activities -$15.82K -$11.21K -$71.21K
YoY Change -19.39% -156.96% -172.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.59M
YoY Change 164751.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.793M 3.380K 10.59M
YoY Change 66.47% -27.78% 164751.85%
NET CHANGE
Cash From Operating Activities -$5.298M -4.969M -24.74M
Cash From Investing Activities -$15.82K -11.21K -71.21K
Cash From Financing Activities $6.793M 3.380K 10.59M
Net Change In Cash $1.479M -4.976M -14.22M
YoY Change -151.53% 9.09% -19.57%
FREE CASH FLOW
Cash From Operating Activities -$5.298M -$4.969M -$24.74M
Capital Expenditures $16.99K $11.38K $71.38K
Free Cash Flow -$5.315M -$4.980M -$24.81M
YoY Change -23.55% 8.11% 39.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1485902
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1485902
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1202677
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1202677
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
172.81
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
175.65
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
57.79
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
172.81
CY2023Q4 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
57.36
CY2022Q4 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
183.42
CY2023Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
123.19
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
134.14
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
121.11
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
123.19
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
124.73
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
129.19
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38244
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0772347
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
3300 Bee Cave Road #650-227
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78746
CY2023 dei City Area Code
CityAreaCode
877
CY2023 dei Local Phone Number
LocalPhoneNumber
774-4679
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
GNPX
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
48500000 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1910441
CY2023 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2023 dei Auditor Location
AuditorLocation
East Brunswick, New Jersey
CY2023 dei Auditor Firm
AuditorFirmId
100
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6737629 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20954069 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34852 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
794138 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
484224 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7531767 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
21473145 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7859 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23032 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10000 usd
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
21818 usd
CY2023Q4 gnpx Research And Development Assets Noncurrent
ResearchAndDevelopmentAssetsNoncurrent
2347488 usd
CY2022Q4 gnpx Research And Development Assets Noncurrent
ResearchAndDevelopmentAssetsNoncurrent
2864937 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
773478 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
702095 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3130966 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3588850 usd
CY2023Q4 us-gaap Assets
Assets
10670592 usd
CY2022Q4 us-gaap Assets
Assets
25085027 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1397610 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
442925 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1856598 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2367362 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3254208 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2810287 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1486 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1203 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
141103178 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
125101356 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-133688280 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102827819 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7416384 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
22274740 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10670592 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25085027 usd
CY2023 us-gaap Revenues
Revenues
0 usd
CY2022 us-gaap Revenues
Revenues
0 usd
CY2023 us-gaap Depreciation
Depreciation
15004 usd
CY2022 us-gaap Depreciation
Depreciation
25575 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17616605 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11510074 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13443961 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12295070 usd
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
31075570 usd
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
23830719 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-31075570 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-23830719 usd
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
215109 usd
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
90098 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-30860461 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-23740621 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-22.56
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-19.8
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1367747
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1198837
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41276991 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6426 usd
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
163232 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4568712 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-23740621 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
22274740 usd
CY2023 gnpx Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
10593377 usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
19010 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5389718 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-30860461 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7416384 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-30860461 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-23740621 usd
CY2023 us-gaap Depreciation
Depreciation
15004 usd
CY2022 us-gaap Depreciation
Depreciation
25575 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
5408728 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
4731944 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-34852 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
34852 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
309914 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-27125 usd
CY2023 gnpx Increase Decrease In Research And Development Supplies
IncreaseDecreaseInResearchAndDevelopmentSupplies
-517449 usd
CY2022 gnpx Increase Decrease In Research And Development Supplies
IncreaseDecreaseInResearchAndDevelopmentSupplies
-157465 usd
CY2023 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-11818 usd
CY2022 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
13127 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
954686 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-530269 usd
CY2023 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-510765 usd
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1755262 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24738603 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17621498 usd
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
169 usd
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
CY2023 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
71383 usd
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
59735 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71214 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59735 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10593377 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6426 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10593377 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6426 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14216440 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17674807 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20954069 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38628876 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6737629 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20954069 usd
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><b>Reclassification of Prior Year Presentation</b></span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had <em style="font: inherit;">no</em> effect on the reported results of operations. An adjustment has been made to the Statement of Cash Flows for the year ended fiscal year ended <em style="font: inherit;"> December 31, 2022</em> to reclassify research and development supplies from an investing activity to an operating activity.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Use of Estimates</i></span></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The preparation of the Company’s financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p>
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
6490117 usd
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
20679538 usd
CY2023Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
2347488 usd
CY2022Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
2864937 usd
CY2023 gnpx Number Of Granted Patents
NumberOfGrantedPatents
21 pure
CY2023 gnpx Number Of Pending Patent Applications
NumberOfPendingPatentApplications
23 pure
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
500
CY2022 gnpx Stock Issued During Period Shares Exercise Of Cashless Warrants
StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
342
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2925
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1485902
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
53695
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
55121
CY2023 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
296273
CY2023 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
38.75
CY2022 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
2575
CY2022 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
61.55
CY2023 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
CY2023 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
CY2022 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
342
CY2022 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
20
CY2023 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
3528
CY2023 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
209.77
CY2022 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
3659
CY2022 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
151.66
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
346440
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
53695
CY2023Q4 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
340585
CY2022Q4 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
47548
CY2022 gnpx Stock Issued During Period Shares Exercise Of Cashless Warrants
StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
342
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
346440
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
57.79
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8342 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
285883
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
8251
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
6245
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
74600
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1668
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M17D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y29D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
284377
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
214370
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
8251
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
30.14
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
74600
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
86.45
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
500
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.92
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2925
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.6
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
6245
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
104.42
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1668
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
101.88
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
285883
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
284377
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
237859
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
167957
CY2023 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
141564 usd
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
74281 usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
0 usd
CY2023Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
0 usd
CY2022Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
0 usd
CY2023Q4 gnpx Deferred Tax Asset Research And Development Expenses
DeferredTaxAssetResearchAndDevelopmentExpenses
4710079 usd
CY2022Q4 gnpx Deferred Tax Asset Research And Development Expenses
DeferredTaxAssetResearchAndDevelopmentExpenses
1986102 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
684699 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
561496 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1434851 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
728701 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
306906 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
94237 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16915002 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14464170 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24051538 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17834706 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1650 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
4354 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
-0 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
-0 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
629136 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
710643 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
-0 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
-0 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
-0 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
-0 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
630786 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
714997 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23420752 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17119710 usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23400000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17100000 usd

Files In Submission

Name View Source Status
0001437749-24-010426-index-headers.html Edgar Link pending
0001437749-24-010426-index.html Edgar Link pending
0001437749-24-010426.txt Edgar Link pending
0001437749-24-010426-xbrl.zip Edgar Link pending
acclaim-1850v3.jpg Edgar Link pending
acclaim-2850v3.jpg Edgar Link pending
acclaim-3850v3.jpg Edgar Link pending
acclaim-3figure1.jpg Edgar Link pending
acclaim-3figure2.jpg Edgar Link pending
acclaim-3figure31.jpg Edgar Link pending
acclaim-3figure32.jpg Edgar Link pending
acclaim-3figure33.jpg Edgar Link pending
acclaim-3figure34.jpg Edgar Link pending
diabetes1_850.jpg Edgar Link pending
diabetes2.jpg Edgar Link pending
diabetes3.jpg Edgar Link pending
diabetes4.jpg Edgar Link pending
diabetes5.jpg Edgar Link pending
diabetes6.jpg Edgar Link pending
diabetes7.jpg Edgar Link pending
diabetes8.jpg Edgar Link pending
diabetes9.jpg Edgar Link pending
ex_600628.htm Edgar Link pending
ex_600629.htm Edgar Link pending
ex_600630.htm Edgar Link pending
ex_600631.htm Edgar Link pending
ex_600632.htm Edgar Link pending
ex_629269.htm Edgar Link pending
ex_636683.htm Edgar Link pending
ex_636684.htm Edgar Link pending
ex_637850.htm Edgar Link pending
ex_637851.htm Edgar Link pending
ex_637852.htm Edgar Link pending
figure1.jpg Edgar Link pending
figure2.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gnpx-20231231.xsd Edgar Link pending
gnpx-20231231_def.xml Edgar Link unprocessable
gnpx-20231231_lab.xml Edgar Link unprocessable
gnpx-20231231_pre.xml Edgar Link unprocessable
gnpx20231231_10k.htm Edgar Link pending
gylze0pdymuz000002.jpg Edgar Link pending
gylze0pdymuz000003.jpg Edgar Link pending
gylze0pdymuz000004.jpg Edgar Link pending
gylze0pdymuz000006.jpg Edgar Link pending
lipoplex850pix.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pipeline_march2024850.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
reqorsatarceva_850v1.jpg Edgar Link pending
Show.js Edgar Link pending
gnpx20231231_10k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
gnpx-20231231_cal.xml Edgar Link unprocessable